Efficacy of canakinumab in mild or severe COVID-19 pneumonia https://doi.org/10.1002/iid3.400 34 patients with mild or severe non intensive care unit (ICU) coronavirus disease 2019 (COVID-19) were enrolled: 17 patients treated with standard therapy and 17 patients treated with a subcutaneous… Continue reading "(20 Jan 2021) Canakinumab- causes rapid and long-lasting improvement in oxygenation levels"
Clinical efficacy of Methylprednisolone and the combined use of Lopinavir/Ritonavir with Arbidol in treatment of Coronavirus Disease 2019 https://doi.org/10.1002/jmv.26798 For all patients, there were no significant differences in the change of body temperature, the time for negative conversion and hospital… Continue reading "(16 Jan 2021) Lopinavir/Ritonavir (LPV/r), Arbidol (ARB) and Methylprednisolone -LPV/r combined with ARB no effect,"
Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study https://doi.org/10.1186/s12879-021-05773-w Among 1274 outpatients with documented SARS-CoV-2 infection 7.6% were prescribed hydroxychloroquine. In a 1067 patient propensity matched cohort, 21.6% with outpatient exposure to hydroxychloroquine were… Continue reading "(16 Jan 2021) Hydroxychloroquine- associated with a decreased rate of subsequent hospitalization"
Matched cohort study on the efficacy of tocilizumab in patients with COVID-19 https://doi.org/10.1016/j.onehlt.2021.100214 The objective of this study is to analyze whether the use of tocilizumab is associated with respiratory improvement and a shorter time to discharge in patients with… Continue reading "(12 Jan 2021) Tocilizumab- No clinical benefit associated with the use tocilizumab"
Antiviral drugs in hospitalized patients with COVID-19 – the DisCoVeRy trial https://www.medrxiv.org/content/10.1101/2021.01.08.20248149v1 NCT04315948- An open-label, randomized, adaptive, controlled trial, multi-center trial was conducted with 583 COVID-19 inpatients requiring oxygen and/or ventilatory support from France. Adjusted Odds Ratio (aOR) for the… Continue reading "(09 Jan 2021) Antivirals, DisCovery trial-No improvement of the clinical status at day 15"
Ivermectin as a potential treatment for mild to moderate COVID-19 – A double blind randomized placebo-controlled trial https://www.medrxiv.org/content/10.1101/2021.01.05.21249310v1 CTRI/2020/08/027225- A total of 115 patients were enrolled for the study of which 112 were included in the final analysis. Of them,… Continue reading "(09 Jan 2021) Ivermectin- negative RT-PCR on day 6 of admission with the use of ivermectin"
Combination therapy of IFNbeta1 with lopinavir-ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients https://doi.org/10.1016/j.intimp.2020.107329 We conducted a retrospective study of all adult confirmed COVID-19 hospitalized patients who received combination of three doses of 12 million international units… Continue reading "(08 Jan 2021) Interferon beta- associated with decrease in death risks"
Heparin in COVID-19 patients is associated with reduced in-hospital mortality: the multicentre Italian CORIST Study https://doi.org/10.1055/a-1347-6070 In a retrospective observational study, 2,574 unselected patients hospitalised in 30 clinical centres in Italy from February 19, 2020 to May 23, 2020 with… Continue reading "(08 Jan 2021) Heparin-Inhospital heparin treatment was associated with lower mortality"
Compassionate use of Ruxolitinib in patients with SarsCov-2 infection not on mechanical ventilation. Short-term effects on inflammation and ventilation https://doi.org/10.1111/cts.12971 Ruxolitinib was provided as a compassionate use in patients consecutively admitted to our institution for Sars-CoV-2 infection. Inclusion criteria were… Continue reading "(07 Jan 2021) Ruxolitinib- was associated with significant reduction of biomarkers of inflammation"
Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double blind dose response study in Lagos https://www.medrxiv.org/content/10.1101/2021.01.05.21249131v1 ISRCTN40302986- a translational proof of concept (PoC) randomized, double blind placebo controlled, dose response, parallel group study of IV efficacy… Continue reading "(06 Jan 2021) Ivermectin-12 mg IV regime may have superior efficacy"
